Author:
Houot Mélanie,Poinsignon Vianney,Mercier Lionel,Valade Cyril,Desmaris Romain,Lemare François,Paci Angelo
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Galton DA. Myleran in chronic myeloid leukaemia; results of treatment. Lancet. 1953;264:208–13.
2. Scott LJ, Hoy SM, Lyseng-Williamson KA. Intravenous busulfan: a guide to its use as a conditioning treatment before transplantation of haematopoietic progenitor cells. Clin Drug Invest. 2012;32:641–8.
3. Busilvex: summary of product characteristics. London: European Medicines Agency. Available from: http://www.medicines.org.uk/emc/medicine/12967/SPC/ .
4. Santos GW. The development of busulfan/cyclophosphamide preparative regimens. Semin Oncol. 1993;20:12–6.
5. Hartmann O, Benhamou E, Beaujean F, et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol. 1986;4:1804–10.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献